Cargando…

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

BACKGROUND: In an effort to establish the lowest effective dose of desvenlafaxine (administered as desvenlafaxine succinate), we assessed the efficacy, safety, and tolerability of 10- and 50-mg/day desvenlafaxine vs placebo for the treatment of major depressive disorder. METHODS: Adult outpatients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liebowitz, Michael R, Tourian, Karen A, Hwang, Eunhee, Mele, Linda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763843/ https://www.ncbi.nlm.nih.gov/pubmed/23517291 http://dx.doi.org/10.1186/1471-244X-13-94

Ejemplares similares

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
por: Katzman, Martin A., et al.
Publicado: (2017)

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder
por: Atkinson, Sarah, et al.
Publicado: (2018)

Desvenlafaxine in the treatment of major depressive disorder
por: Lourenco, Maria Teresa C, et al.
Publicado: (2009)

Desvenlafaxine
por: Andrade, Chittaranjan
Publicado: (2009)

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
por: Weihs, Karen L., et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
por: Gommoll, Carl P., et al.
Publicado: (2014)

Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy
por: Lieberman, Daniel Z, et al.
Publicado: (2010)

Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study
por: Tfelt-Hansen, P., et al.
Publicado: (2006)

Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine
por: Benoit, James R.A., et al.
Publicado: (2021)

Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)
por: Patel, Jaimin M, et al.
Publicado: (2012)

Is Desvenlafaxine Effective and Safe in the Treatment of Menopausal Vasomotor Symptoms? A Meta-analysis and Meta-regression of Randomized Double-blind Controlled Studies
por: Berhan, Yifru, et al.
Publicado: (2014)

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Mathews, Maju, et al.
Publicado: (2015)

Venlafaxine and desvenlafaxine in the management of menopausal hot flashes
por: Johnson, Emily D, et al.
Publicado: (2011)

Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
por: Olié, Jean-Pierre, et al.
Publicado: (2010)

Efficacy of prednisone 1–4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial
por: Pincus, T, et al.
Publicado: (2009)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Drug–drug interactions involving antidepressants: focus on desvenlafaxine
por: Low, Yvette, et al.
Publicado: (2018)

Desvenlafaxine-Induced Interstitial Pneumonitis: A Case Report
por: Flora, Arjan, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials
por: Adler, Lenard A., et al.
Publicado: (2022)

Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study
por: Vicknasingam, Balasingam, et al.
Publicado: (2020)

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
por: Boulenger, Jean-Philippe, et al.
Publicado: (2014)

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
por: Roh, Sungwon, et al.
Publicado: (2022)

Effect of 10-Day Treatment with 50 mg Prednisolone Once-Daily on Haemostasis in Healthy Men—A Randomised Placebo-Controlled Trial
por: Kamstrup, Peter, et al.
Publicado: (2023)

Prenatal desvenlafaxine induced behavioural alterations in Swiss albino mice
por: Kumari, Amrita, et al.
Publicado: (2014)

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
por: Soares, Claudio N., et al.
Publicado: (2019)

Desvenlafaxine-associated hyperglycemia: A case report and literature review
por: Mekonnen, Andrea D., et al.
Publicado: (2020)

Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets
por: Carapeto, Gustavo Vaiano, et al.
Publicado: (2023)

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan
por: Watanabe, Yoshinori, et al.
Publicado: (2018)

A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder
por: Papakostas, G. I., et al.
Publicado: (2019)

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study
por: van de Loo, Aurora J. A. E., et al.
Publicado: (2017)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study
por: Rancans, Elmars, et al.
Publicado: (2020)

Almotriptan 12.5 mg in menstrually related migraine: A randomized, double-blind, placebo-controlled study
por: Allais, Gianni, et al.
Publicado: (2011)

The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis
por: Zheng, Jiahuan, et al.
Publicado: (2019)

Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy
por: Allen, Rob, et al.
Publicado: (2014)

LC–UV and LC–MS evaluation of stress degradation behavior of desvenlafaxine
por: Pawar, Shubhangi M., et al.
Publicado: (2012)

Periodontal status in chronic periodontitis depressed patients on desvenlafaxine: An observational study
por: Bhatia, Anu, et al.
Publicado: (2018)

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets
por: Samy, Wael, et al.
Publicado: (2017)

Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery
por: Tong, Gui-Feng, et al.
Publicado: (2017)

A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
por: Ch, Saritha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9jhbp4215g6oa1cb8cpfsqc78f